[{"from": "human", "value": "Describe this molecule. [C][C][=C][Branch2][Ring1][S][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][=Branch1][=N][C][=C][Ring1][Branch2][N][C][=C][Branch1][#Branch2][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][Cl][F][N][C][=Branch1][C][=O][C][=C][S][C][=C][Ring1][Branch1][N][=C][N][=C][Ring1][=Branch1][N]"}, {"from": "gpt", "value": "The molecule is an orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway."}]